Anti-EGFRvIII Antibody, clone DH8.3

Epidermal growth factor receptor (UniProt: P00533; also known as EC:2.7.10.1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1) is encoded by the EGFR (also known as ERBB, ERBB1, HER1) gene (Gene ID: 1956) in human. EGFR is a single-pass type 1 membrane protein that is ubiquitously expressed. It is synthesized with a 24 amino acids signal peptide that is subsequently cleaved. It contains an extracellular domain (aa 25-645) a transmembrane domain (aa 646-668), and a cytoplasmic domain (aa 669-1210). Upon binding of EGF, the receptor is phosphorylated and recruits adapter proteins to turn on downstream signaling cascades. EGFR is commonly overexpressed and is mutated in many human malignancies and is often associated with aggressive phenotypes. The most common truncated EGFR is the variant III EGFR deletion mutant (EGFRvIII), containing an inframe deletion of exons 2 7 (801 bp) from the extracellular domain. EGFRvIII mutation is reported in about 5% of human lung squamous cell carcinoma (SCC). It has also been suggested that EGFRvIII potentially plays an essential role in the human NSCLC tumor initiation and maintenance. Drugs such as Gefitinib, erlotnib, and HKI-272 are shown to inhibit the growth of EGFRvIII transformed cells and tumor growth. (Ref.: Ji, H., et al. (2006). Proc. Natl. Acad. Sci. USA 103(20); 7817-7822).

Clone DH8.3 detects EGFR variant vIII a truncated form of EGFR, present in human cancer cells.

KLH-conjugated linear peptide corresponding to EGFRvIII (EGFR variant III) (LEEKKGNYVVTDHC) sequence.

Anti-EGFRvIII, clone DH8.3, Cat. No. MABS1915, is a mouse monoclonal antibody that specifically detects epidermal growth factor receptor vIIIa and has been tested for use in ELISA, Flow Cytometry, Immunohistochemistry, Immunoprecipitation, and Western Blotting.

Research Category
Signaling

Western Blotting Analysis: A representative lot detected EGFRvIII in Western Blotting applications (Lammering, G., et. al. (2004). Clin Cancer Res. 10(19):6732-43; Nishikawa, R., et. al. (2004). Brain Tumor Pathol. 21(2):53-6; Hills, D., et. al. (1995). Int J Cancer. 63(4):537-43).

Flow Cytometry Analysis: A representative lot detected EGFRvIII in Flow Cytometry applications (Johns, T.G., et. al. (2002). Int J Cancer. 98(3):398-408; Hills, D., et. al. (1995). Int J Cancer. 63(4):537-43).

Immunohistochemistry Analysis: A representative lot detected EGFRvIII in Immunohistochemistry applications (Jungbluth, A.A., et. al. (2003). Proc Natl Acad Sci USA. 100(2):639-44; Nishikawa, R., et. al. (2004). Brain Tumor Pathol. 21(2):53-6; Feng, H., et. al. (2014). J Clin Invest. 124(9):3741-56; Feng, H., et. al. (2012). Proc Natl Acad Sci USA. 109(8):3018-23.

Immunoprecipitation Analysis: A representative lot detected EGFRvIII in Immunoprecipitation applications (Lammering, G., et. al. (2004). Clin Cancer Res. 10(19):6732-43; Hills, D., et. al. (1995). Int J Cancer. 63(4):537-43).

ELISA Analysis: A representative lot detected EGFRvIII in ELISA applications (Johns, T.G., et. al. (2002). Int J Cancer. 98(3):398-408; Hills, D., et. al. (1995). Int J Cancer. 63(4):537-43).

Evaluated by Western Blotting in U87MG.∆EGFR cell lysates.

Western Blotting Analysis: 4 ug/mL of this antibody detected EGFRvIII in 10 µg of U87MG.∆EGFR cell lysates.

~140 kDa observed; 134.28 kDa calculalted. Uncharacterized bands may be observed in some lysate(s).

Protein G purified

Format: Purified

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.

Concentration: Please refer to lot specific datasheet.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.